2019
DOI: 10.1007/s11427-019-9582-9
|View full text |Cite
|
Sign up to set email alerts
|

A specific assay for JmjC domain-containing lysine demethylase and its application to inhibitor screening

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 14 publications
0
1
0
Order By: Relevance
“…The importance of histone methylation is also being demonstrated by emerging evidence that links histone methylation to disease and ageing. At present, a select group of demethylase inhibitors is being evaluated in clinical trials (Wen et al, 2019). One of the most studied inhibitors is tranylcypromine, which efficiently inhibits KDM1A by forming a covalent adduct with the FAD cofactor, and two clinical trials using tranylcypromine to cure acute myeloid leukemia and myelodysplastic syndrome are underway (Jambhekar et al, 2017).…”
Section: Perspectives and Concluding Remarksmentioning
confidence: 99%
“…The importance of histone methylation is also being demonstrated by emerging evidence that links histone methylation to disease and ageing. At present, a select group of demethylase inhibitors is being evaluated in clinical trials (Wen et al, 2019). One of the most studied inhibitors is tranylcypromine, which efficiently inhibits KDM1A by forming a covalent adduct with the FAD cofactor, and two clinical trials using tranylcypromine to cure acute myeloid leukemia and myelodysplastic syndrome are underway (Jambhekar et al, 2017).…”
Section: Perspectives and Concluding Remarksmentioning
confidence: 99%